A generics powerhouse worth some $20 billion in revenues is to be created by the merger of Netherlands-incorporated Mylan and the off-patent business of New Yor 29 July 2019
Months after reports indicated that Aurobindo Pharma would bid for the US-based generics firm Sandoz, parent company Novartis announced it had accepted an offer 7 September 2018
Switzerland’s Novartis is moving to offload its American dermatology business and oral treatments division, among other assets, for up to $2 billion. 14 May 2018